EGFR and non-small cell lung carcinoma: Even worse, it was reported that the medication adherence of patients receiving EGFR-TKI-based targeted therapy was poor, with 32% of NSCLC patients terminating treatments due to skin toxicity reactions, which compromised the treatment effects [16, 17].